학술논문
The Lipid-Platelet Interplay: Unraveling the Effects of PCSK9 Inhibition on Platelet Reactivity.
Document Type
Editorial & Opinion
Author
Ortega-Paz L; Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.; Franchi F; Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.; Angiolillo DJ; Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, United States.
Source
Publisher: Thieme Country of Publication: Germany NLM ID: 7608063 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2567-689X (Electronic) Linking ISSN: 03406245 NLM ISO Abbreviation: Thromb Haemost Subsets: MEDLINE
Subject
Language
English
Abstract
Competing Interests: F.F. has received payment as an individual for consulting fees or honoraria from AstraZeneca, Bayer, and Sanofi; and has received institutional payments for grants from PLx Pharma and the Scott R. MacKenzie Foundation. D.J.A. declares that he has received consulting fees or honoraria from Abbott, Amgen, Astra-Zeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, CSL Behring, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, Novartis, Novo Nordisk, PhaseBio, PLx Pharma, Pfizer, Sanofi, and Vectura; he also declares that his institution has received research grants from Amgen, AstraZeneca, Bayer, Biosensors, Celo-Nova, CSL Behring, Daiichi-Sankyo, Eisai, Eli Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, and the Scott R. MacKenzie Foundation. L.O.-P. has nothing to declare.